SHP2 Inhibitor Signal pathway: RAS、I/OView More

 

JAB-3068 is theF second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).

As date of Aug 23, 2022
  • U.S.
  • China
  • Global

JAB-3312


Therapy Indications Phase I Phase IIa Recent progress
KRAS G12Ci Combination Therapy KRAS G12C mut NSCLC
 
 
 
Phase IIa initiated in
Jul, 2022
Combo w/EGFRi Osimertinib progressed NSCLC
 
 
 
FPI in
Jan, 2022
Combo w/PD-1 mAb NSCLC, HNSCC, ESCC
 
 
 
Phase IIa initiated with FPI in
Feb, 2022
Mono BRAF Class 3/NF1 LOF mutant solid tumers
 
 
 
 

 

JAB-3068


Therapy Indications Phase I Phase IIa Recent progress
Mono ESCC, HNSCC, NSCLC, ACC
 
 
 
 
Combo w/PD-1 mAb ESCC, HNSCC, NSCLC
 
 
 
 

KRAS G12C Inhibitor Signal pathway: RASView More

JAB-21822

JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.

As date of Sep 16, 2022
  • U.S.
  • China
  • Global

JAB-21822

Therapy Indications Phase I Phase IIa Pivotal Recent progress
Mono NSCLC
 
 
 
Pivotal study FPI
in Sep 2022
Mono CRC, PDAC and other solid tumors
 
 
 
  Phase IIa FPI
in Mar 2022
Mono
Combo w/EGFR mAb
NSCLC, CRC, PDAC
 
 
 
  FPI in May 2022
in Europe
Mono 1L NSCLC with STK11 co-mutation
 
 
 
 

FPI in China

in Sep 2022

Combo w/SHP2i Advanced solid tumors
 
 
 
  FPI in
May 2022
Combo w/EGFR mAb CRC
 
 
 
  Phase IIa FPI
in Jul 2022
Combo w/PD-1 mAb NSCLC
 
 
 
   

BET Inhibitor Signal pathway: MYC View More

JAB-8263

JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have shown that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.

As date of March 31, 2022
  • U.S.
  • China
  • Global

JAB-8263

Therapy Indications IND Phase I Phase II Recent progress
Monotherapy Solid Tumor
 
 
 
 
Monotherapy Solid Tumor
 
 
 
First patient enrolled
Feb, 2022
Monotherapy MF, AML
 
 
 
First patient enrolled
Apr, 2021

Aurora A inhibitor Signal pathway: RBView More

JAB-2485

JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.

As date of March 31, 2022
  • U.S.
  • China
  • Global

JAB-2485

Therapy Indications IND Phase I Phase II Recent progress
Monotherapy Solid Tumor
 
 
 
IND Approved
Jan, 2022

CD73 monoclonal antibody Signal pathway: I/OView More

JAB-BX102

JAB-BX102 is a humanized anti-CD73 monoclonal antibody (mAb)developed by Jacobio to inhibit the enzymatic activity of CD73. CD73 is the key node of adenosine pathway, and its inhibitors have broad therapeutic prospects for tumors dependent on adenosine pathway. Relevant studies have shown that adenosine promotes SHP2 phosphorylation, suggesting that anti-CD73 antibody can be combined with SHP2 inhibitor, which is also developed by Jacobio to benefit patients with advanced solid tumors.

As date of Sep 6, 2022
  • U.S.
  • China
  • Global

JAB-BX102

Therapy Indications IND Phase I Phase IIa Recent progress
Mono and Combo w/ PD-1 antibody Solid Tumor
 
 
 
FPI in China
Sep, 2022

IND-enabling Stage Candidates

 

  Asset Target Modality IND Schedule Indications Recent Development Lead Optimization IND-enabling
IND-Enabling
JAB-26766 PARP7
(I/O)
Small molecule 2022 IND Solid tumors Candidate nominated, entering into IND
enabling studies in Jan 2022
 
 
JAB-24114 Undisclosed
(Tumor metabolic pathway)
Small molecule 2022 IND Solid tumors, Hematological malignancies Candidate nominated, entering into IND
enabling studies in Mar 2021
 
 
JAB-BX300 Undisclosed
(RAS pathway)
Monoclonal antibody 2022 IND Solid tumors Candidate nominated, entering into IND
enabling studies in Mar 2021
 
 
JAB-23400 KRASmulti
(RAS pathway)
Small molecule 2023 IND PDAC, CRC, NSCLC Candidate nominated, entering into IND
enabling studies in Feb 2021
 
 
JAB-30300 P53 Y220C
(P53 pathway)
Small molecule 2023 IND Solid tumors Candidate nominated, entering into IND
enabling studies in Jul 2022
 
 
Lead Optimization
JAB-BX400 HER2-STING
(I/O)
iADC 2024 IND Solid tumors Payload has been selected and patent filed in Dec 2021
 
 
JAB-X1800 CD73-STING
(I/O)
iADC 2024 IND Solid tumors Payload has been selected and patent filed in Dec 2021
 
 
JAB-22000 KRAS G12D
(RAS pathway)
Small molecule 2024 IND PDAC, CRC, NSCLC Lead series identified and patent filed in Nov 2020
 
 

Abbreviation: mAb = monoclonal antibody; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non CLC; KRAS amp = KRAS amplification; Lof = missing function; CRC = colorectal cancer; MF = bone marrow fibrosis; AML = acute myeloid leukemia; CRPC = castration resistant prostate cancer; HCC = hepatocellular carcinoma; PDAC = pancreatic ductal adenocarcinoma; Ind = new drug for clinical research or new drug application for clinical research.

As date of Sep 6, 2022